Hematopoietic Stem Cell Transplantation (HSCT) Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies…

Industry Growth Insights (IGI) has included a latest report on the Global Hematopoietic Stem Cell Transplantation (HSCT) Market into its archive of market research studies. The report is an amalgamation of detailed market overview based on the segmentations, applications, trends and opportunities, mergers and acquisitions, drivers, and restraints. The report showcases the current and forthcoming technical and financial details of the Hematopoietic Stem Cell Transplantation (HSCT) market. The research study attracts attention to a detailed synopsis of the market valuation, revenue estimation, and market statistics. The study on the emerging trends in the global and regional spaces on all the significant components, such as market capacity, cost, price, demand and supply, production, profit, and competitive landscape. The report also explores all the key factors affecting the growth of the global market, consisting of the demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Some of the major companies that are covered in this report:

*Note: Additional companies can be included on request

Get a free exclusive sample report of Hematopoietic Stem Cell Transplantation (HSCT) market @ https://industrygrowthinsights.com/request-sample/?reportId=194325

Impact of COVID-19

The report also talks about the impact of the ongoing global crisis i.e., COVID-19 on the Hematopoietic Stem Cell Transplantation (HSCT) market and explains how the future is going to unfold for the global market. Our analysts have researched thoroughly about the effects of the pandemic on the global economy. The outbreak has directly affected production and demand disrupted the demand and supply chain. The report also computes the financial impact on firms and financial markets. Industry Growth Insights (IGI) has accumulated insights from several delegates of the industry and got involved in the primary and secondary research to offer the clients data & strategies to combat the market challenges during and after the COVID-19 pandemic.

Highlights of the report:

Our research analysts who are the building blocks of the company have worked extensively to fabricate the research report which will give that extra edge to our clients business in the competitive market. The market research report can be customized as per you and your needs. This means that Industry Growth Insights (IGI) can cover a particular product, application, or can offer a detailed analysis in the report. You can also buy a separate report for a specific region.

You can buy the complete report in PDF format: @ https://industrygrowthinsights.com/checkout/?reportId=194325

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Applications:

By Types:

By Regions:

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is integrated into the report is the regional analysis to assess the global presence of the Hematopoietic Stem Cell Transplantation (HSCT) market. You can also opt for a yearly subscription of all the updates on the Hematopoietic Stem Cell Transplantation (HSCT) market.

If you have any questions on this report, feel free to reach us! @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=194325

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Hematopoietic Stem Cell Transplantation (HSCT) Market Overview

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast by Type

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast by Application

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast by Sales Channel

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast by Region

North America Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast

Latin America Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast

Europe Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast

Asia Pacific Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast

Asia Pacific Hematopoietic Stem Cell Transplantation (HSCT) Market Size and Volume Forecast by Application

Middle East & Africa Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis and Forecast

Competition Landscape

Avail exclusive discount on this report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=194325

About Industry Growth Insights (IGI):

Industry Growth Insights (IGI) has a vast experience in making customized market research reports in a number of industry verticals. We strive for complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. Our team makes sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://industrygrowthinsights.com

View original post here:

Hematopoietic Stem Cell Transplantation (HSCT) Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies...

Read more
Black people are three times less likely to find a bone marrow donor than white people – WLNS

LANSING, Mich. (WLNS) More than three-quarters of African Americans are unable to find a bone marrow or stem cell transplant who need one, according to the nations largest bone marrow registry, Be the Match.

There are more than 20 million people on the registry, a database of people who volunteer to donate their stem cells or bone marrow if theyre found to be a match to someone seeking a transplant, and oftentimes, a transplant can mean giving people a second chance at life.

In fact, a blood stem cell transplant can be a cure for more than 70 diseases including blood cancer (leukemia, lymphoma, etc), sickle cell anemia and aplastic anemia to name a few.

However, the likelihood for people of color and Black people specifically, is staggeringly low.

Every year, millions of people are diagnosed with a life-threatening blood disorder.

That means millions of people are looking for a donor, someone whose special protein cells, called HLA proteins, match their own.

Patients are most likely to match donors who share the same ethnic background, according to Be the Match, but this is not always the case.

There is a catch though more often than not, there are not enough donors available and willing to give blood.

As the coronavirus pandemic has struck the world and cut blood donations severely, the challenge of finding a blood donor match has become more difficult.

Charles Poldo is a 51-year-old Black man living in mid-Michigan. In 2012, Poldo was diagnosed with acute myeloid leukemia, a type of cancer of the blood and bone marrow with excess immature white blood cells.

Acute myeloid leukemia runs in his family too but Poldo said he was determined to beat the cancer.

My mom and her dad died from it so when I got diagnosed, I knew I was not going to die, Poldo said.

So, Poldo embarked on a 7 year-long search for a donor.

But doctors could not find anyone of the more than 20+ million people on the Be the Match Registry who were exactly compatible with Poldo.

Doctors decided to proceed with an imperfect solution and Poldo received a treatment that did not fully cure his AML.

As a result, Poldo went into remission and was re-diagnosed with AML again in Nov. 2019.

By this time, technology had advanced to where Poldo could receive an imperfect match.

Even so, Poldos scenario is not an ideal one, especially because of the adverse effects of an imperfect match namely, his own immune system attacking and rejecting the donors cells.

In the medical field, they refer to this adverse effect as a post-transplant complication or graft-versus-host (GVHD) disease.

In Feb. 2020 just before the pandemic hit, Poldo received an umbilical cord transplant, which uses stem cells from umbilical cords donated at the time of a persons birth for instances like these.

Fortunately, Poldos immune system did not reject his transplants. But thats not the case for everyone.

Poldo said the person whose umbilical cord he received is now 8 years old. While he did not have the opportunity to meet his donor face-to-face, he is thankful.

Poldo is one of many African Americans who are unable to find a donor whose proteins match up exactly.

Even though Poldos transplant was successful, others are not as lucky.

People of color are underrepresented in the registry for a number of reasons, although there is no clear evidence as to why.

According to CBS News, a couple of reasons why people of color are underrepresented include a history of medical abuse of Black people in healthcare research, a lack of multi-lingual resources and stigma or fear of donating out of health concerns.

The Black community is more likely to be skeptical to sign up to be volunteers for medical trials or even the registry due to their abuse and mistreatment by medical researchers in the past.

For example, the 1932 Tuskegee syphilis trials also known as: Tuskegee Study of Untreated Syphilis in the Negro Male purposely infected several hundred Black people with syphilis without their informed consent or cure of the disease.

The trial that was supposed to last six months ended up lasting 40 years.

In addition, language barriers and access to knowledge about donating blood and stem cells exist among minority communities including Asian, Hispanic and Black people.

Here are some facts that Be the Match has clarified for those on the fence about donating.

Many mistakenly believe that donating blood stem cells is painful, when in reality its not.

It is a common misconception that donating blood stem cells is dangerous. The truth is that there are few risks in donating blood stem cells.

Many people think that donating to a patient in need is expensive for them, but Be The Match covers every cost related to donation.

If you are interested in signing up for the national bone marrow registry, text cure29 to 61474Or join.bethematch.org/cure29

Read this article:

Black people are three times less likely to find a bone marrow donor than white people - WLNS

Read more
Therapeutic Solutions International Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide…

ELK CITY, Idaho, March 4, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today preclinical results and filing of a patent covering the use of manipulated cord blood derived monocytes for prevention of suicidal ideations as well as inflammation of the brain. Company scientists found that administration of non-stem cell components of cord blood to mice exposed to brain inflammation resulted in protection of neurological function as well as suppression of immunological proteins associated in humans with suicidal thoughts.

Paradoxically, it was found that the monocyte component of cord blood was associated with therapeutic activity. Monocytes are typically inflammation inducing cells. Through a trial and error process, the Company found oxytocin pretreatment under proprietary conditions resulted in protection of neurological function (Morris Water Maze) and reduction of inflammation in preclinical studies.

"The fact that the fetus is not immunologically rejected by the mother, despite being genetically incompatible is still largely unexplained," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "We believe that these monocytes possess unique properties that stop the mother's immune system from rejecting the offspring. The data suggests that these same properties may be harnessed to stop inflammation of the brain, which predisposes to suicide."

"While great advances have been made in development of small molecule drugs, there is a growing appreciation for new cell therapies. A recent example is the >$150 million capital raise for a preclinical stage cellular immunotherapy company,1" stated Famela Ramos, Vice President of Business Development of Therapeutic Solutions International. "Given easy access to cord blood and economical cost of production, we are eager to continue our preclinical work and advance to FDA IND filing."

"Campbell Neurosciences recently announced positive results of our Campbell Score blood based suicidal propensity clinical trial," said Kalina O'Connor, President and Chief Executive Officer of Campbell Neurosciences. "Given that the inflammatory proteins that were reduced in preclinical studies are similar to those assessed by the Campbell Score in patients, we are optimistic about clinical translation of this novel approach to preventing suicide."

"The current data and patent filing exemplifies the synergistic relationship between us and our spin-off," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "The discovery was facilitated by experimentation during production of StemVacs, our umbilical cord derived cancer vaccine. It was observed that monocytes, which are also used to produce immune stimulatory dendritic cells, can acquire radically different properties based on growth conditions which we control in a proprietary manner. We plan to collaborate closely for clinical translation of this unique approach to a psychiatric condition."

About Therapeutic Solutions International, Inc.Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline (prnewswire.com)


SOURCE Therapeutic Solutions International


See the article here:

Therapeutic Solutions International Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide...

Read more
Global Hematopoietic Stem Cells Transplantation Market 2020 In-depth study, Size, Trends, Emerging Growth Factors and Regional Forecast to 2025 The…

The latest published report namelyGlobal Hematopoietic Stem Cells Transplantation Market Growth (Status and Outlook) 2020-2025 added byMarketandResearch.bizoffers an insightful take on the historical data of the market and predictions for 2020 to 2025 time-period. The report provides an understanding of the global Hematopoietic Stem Cells Transplantation industry competitors, the sales channel, growth potential, potentially disruptive trends, industry product innovations and the value/volume of size, market segments, and market share of the best actors/products. Current market trends and dynamics are assessed which helps in mapping the track of the global market. A chapter-wise format has been used to ease the readability and complexity of the data. Each chapter is further categorized into its respective segments containing well-structured data.

Market Competition:

The competitive landscape of the global Hematopoietic Stem Cells Transplantation market is examined in detail in the report. The competitive scenario displayed includes major market player details such as company profile, end-user demand, import/export volume, sales data, etc. The business strategies applied by different players are highlighted which will be a great addition to smart business decisions. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production, sales, and earnings. Additionally, analysts have also provided a detailed list of the strategic initiatives taken by the market participants in the past few years.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/129377

Our best analysts have surveyed the market report with the reference of inventories and data given by the key players: CBR Systems, ThermoGenesis, China Cord Blood Corporation, Thermo Fisher Scientific, STEMCELL Technologies, ViaCord, Lonza Group, Vcanbio, CellGenix Technologie Transfer, Merck Millipore

Most important types of products covered in this report are: Stem Cells Storage, Stem Cells Consumables

Most widely used downstream fields of market covered in this report are: Leukemia, Lymphoproliferative Disorders, Solid Tumors, Non-Malignant Disorders

The study broadly exemplifies, the regional hierarchy of this market, while categorizing the same into: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Furthermore, the report includes the growth rate of the global Hematopoietic Stem Cells Transplantation market, consumption tables, facts, figures, and statistics of key segments. The research study delivers market definition and market dynamics, containing drivers, restraints, challenges, threats, and potential development opportunities. The research provides an analysis of indirect and direct sales channels, helps you to plan the right distribution strategy, and understand your customers.

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/129377/global-hematopoietic-stem-cells-transplantation-market-growth-status-and-outlook-2020-2025

Questions That The Market Report Answers With Respect To The Segmentation of The Vertical:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:[emailprotected]Web:www.marketandresearch.biz

Go here to read the rest:

Global Hematopoietic Stem Cells Transplantation Market 2020 In-depth study, Size, Trends, Emerging Growth Factors and Regional Forecast to 2025 The...

Read more
Why Global Cord Blood Corporation Stock Is Jumping Today – Motley Fool

What happened?

Shares of Global Cord Blood Corporation (NYSE:CO), a provider of umbilical cord blood stem cells storage, are rising sharply on Tuesday, following the company's announcement of an unsolicited non-binding acquisition proposal. As of 12:25 p.m. EST, Global Cord Blood's stock was up by 11.5% after popping by as much as 14.6% earlier in the day.

Global Cord Blood announced that it has received an acquisition proposal letter from Alternate Ocean Investment Company Limited, a subsidiary of Hong Kong-based investment bank Haitong International Securities Group Limited. Alternate Ocean is acting on behalf of an unnamed third party in this proposed transaction.

The offer is to acquire all outstanding shares of Global Cord Blood for $5 per share. The company's shares closed Monday's trading session at $4.32 apiece.

Image source: Getty Images.

The roughly 15.7% premium (based on Global Cord Blood's closing price as of yesterday) explains why investors are bidding up shares of the healthcare company today. However, it's important to remember that this offer isn't a binding one at this time. Global Cord Blood's board of directors will discuss the proposed acquisition and decide whether to move forward with it or reject it.

What should long-term investors do with this news? Trying to profit off the short-term gains that Global Cord Blood is experiencing today is certainly a risky move. After all, if the company's board of directors decides to reject the acquisition offer, its stock could fall. And if the offer advances, it's much better to decide whether to buy Global Cord Blood's stock based on its underlying business (and that of its would-be acquirer) than based primarily on today's news.

In other words, like much of the day-to-day fluctuations on the stock market, there isn't too much to see here for investors focused on the long game.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.


Why Global Cord Blood Corporation Stock Is Jumping Today - Motley Fool

Read more
NYCU shares lung therapy data with firms –

A National Yang Ming Chiao Tung University (NYCU) research team has transferred the technology for its experimental stem cell therapy for pulmonary fibrosis to two biotech companies, the first step toward beginning clinical trials, it announced on Friday.

The team led by Fu Yu-show (), a professor in the universitys Institute of Anatomy and Cell Biology, first published details of its therapy, which involves transplanting stem cells collected from umbilical cord fluid into lungs affected by fibrosis, in the international medical journal Theranostics in 2019.

At a ceremony on Friday, Fu and her team said they have agreed to transfer the research to two local biotech firms, Fuhwasheng Regenerative Medicine Co and Taiwan Bio Theraputics Co, in preparation for domestic clinical trials.

Pulmonary fibrosis is a disease characterized by the progressive scarring and thickening of tissue in the lungs, which can be caused by factors such as smoking, air pollution, infection or aging, Fu said.

Because the scarring is permanent, and there are no medications to reverse the damage, treatment has typically focused on easing symptoms and improving quality of life, she said.

The team found that umbilical stem cells transplanted into the lungs of mice with the disease not only survived, but also secreted growth hormones capable of reducing inflammation, Fu said.

Aside from its anti-inflammatory effects, the therapy also promoted the degradation of collagen, a protein in scar tissue, and stimulated the regeneration of alveoli, the tiny sacs in the lungs responsible for the intake of oxygen, she said.

Mice that were given the therapy experienced higher blood oxygen saturation and lower respiratory rates, indicating deeper and less strained breathing, Fu said.

After publishing the results of the study, the team received inquiries from a number of pulmonary fibrosis patients and their families from around the world, leading them to find commercial partners that could help bring the treatment to market, she said.

NYCU president Lin Chi-Hung () said that Fridays event marked the universitys first technology transfer since National Yang-Ming University in Taipei and National Chiao Tung University in Hsinchu merged earlier this month.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

Read the original post:

NYCU shares lung therapy data with firms -

Read more
Covid-19 Impact on Global Stem Cells Cryopreservation Equipments Market (2020-2025) | Potential growth, attractive valuation make it is a long-term…


Latest research report, titled Global Stem Cells Cryopreservation Equipments Market Insights, Forecast to 2025. this report included a special section on the Impact of COVID-19. Also, Stem Cells Cryopreservation Equipments Market (By major Key Players, By Types, By Applications, and Leading Regions) Segments outlook, Business assessment, Competition scenario and Trends .The report also gives 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the strength, weaknesses, opportunities, and threats in front of the businesses. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries. Players can use this study to explore untapped Stem Cells Cryopreservation Equipments markets to extend their reach and create sales opportunities.

Top Key players profiled in the report include:Chart, Worthington Industries, Cesca Therapeutics, Shengjie Cryogenic Equipment, Sichuan Mountain Vertical, Qingdao Beol and More

To Get PDF Sample Copy of the Report(with covid 19 Impact Analysis): https://www.globmarketreports.com/request-sample/18371Stem Cells Cryopreservation Equipments market competitive landscape offers data information and details by companies. Its provides a complete analysis and precise statistics on revenue by the major players participants for the period 2020-2025. The report also illustrates minute details in the Stem Cells Cryopreservation Equipments market governing micro and macroeconomic factors that seem to have a dominant and long-term impact, directing the course of popular trends in the global Stem Cells Cryopreservation Equipments market.Major Type of Stem Cells Cryopreservation Equipments Market: Liquid Phase Vapor PhaseApplication Segments Market: Cord Blood Stem Cells cryopreservation Other Stem Cells CryopreservationRegions Covered in the Global Stem Cells Cryopreservation Equipments Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025Get Chance of up to 30% Extra Discount @ https://www.globmarketreports.com/request-discount/18371Reasons to buy:

Some Major TOC Points:

For More Information with including full TOC: https://www.globmarketreports.com/industry-reports/18371/Stem-Cells-Cryopreservation-Equipments-marketCustomization of the Report:Glob Market Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.Get Customization of the [emailprotected]: https://www.globmarketreports.com/report/request-customization/18371/Stem-Cells-Cryopreservation-Equipments-marketGet in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: [emailprotected]

Go here to read the rest:

Covid-19 Impact on Global Stem Cells Cryopreservation Equipments Market (2020-2025) | Potential growth, attractive valuation make it is a long-term...

Read more
Autologous Stem Cell Based Therapies Market Analysis By Industry Value, Size, Top Companies And Growth Forecast To 2025 KSU | The Sentinel Newspaper…

Autologous Stem Cell Based Therapies Market Summary 2021 :

The Autologous Stem Cell Based Therapies Market report presents the comprehensive analysis of key market segments and sub-segments, evolving the Autologous Stem Cell Based Therapies markettrends and dynamics, changing supply and demand scenarios, Quantifying market opportunities through market sizing and market forecasting, Tracking current trends/opportunities/challenges, competitive insights, opportunity mapping in terms of technological breakthroughs.

This Autologous Stem Cell Based Therapies Market Report covers the manufacturers data, including shipment, price, revenue,gross profit, interview record,business distribution, etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume, and value, as well as price data.

Manufacturer Detail: Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics, Tigenix, Med cell Europe

Get a Sample PDF Report:http://marketresearchvision.com/request-sample/558358

The research report displays growth opportunities over the forecast period, while also highlighting the market drivers, constraints, threats, challenges, competitive landscape, and other key aspects, such as the supply chain with regards to the market.

Segment by Type, the product can be split into, Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells, Market

Segment by Application, split intoNeurodegenerative DisordersAutoimmune DiseasesCardiovascular Diseases

The prime objective of this Autologous Stem Cell Based Therapies report is to define the size of the different segments and the geographies as well as to forecast the trends that are likely to gain traction in the following couple of years. This research report has been designed to incorporate both the qualitative and quantitative aspects of the industry within each of the regions.

With all these analyses and information, this report can act as a valuable guide to readers looking to gain a clear understanding of all the factors that are influencing the market for Autologous Stem Cell Based Therapies market at present and are projected to remain to do so over the forecast period.

Additionally, the information on the latest developments in this Autologous Stem Cell Based Therapies market, both, at the as well as regional level, is expected to enhance the decision-making capability of the reader. Up-to-date information on various specifications, buyer analysis, their purchasing volume, prices, and price analysis, and deep insights on the leading suppliers have also been provided in this study for the readers.

Get Discount on this Report:http://marketresearchvision.com/check-discount/558358?utm_source=Mj

Geographically, thisAutologous Stem Cell Based Therapies report is segmented into several key regions, with sales, revenue, market share (%) and growth rate (%) of the Autologous Stem Cell Based Therapies in these regions, covering

Research objectives:-

Overall the report offers detailed coverage of the Autologous Stem Cell Based Therapies industry and presents main market trends. This research gives historical and forecasts market size, demand and production forecasts, end-use demand details, price trends, and company shares of the leading Autologous Stem Cell Based Therapies producers to provide exhaustive coverage of the market.

Read Complete Report With TOC:http://marketresearchvision.com/reports/558358/Global-Autologous-Stem-Cell-Based-Therapies-Market?utm_source=Mj

If you have any special requirements, please let us know and we will offer you the report as you want.


Autologous Stem Cell Based Therapies Market Analysis By Industry Value, Size, Top Companies And Growth Forecast To 2025 KSU | The Sentinel Newspaper...

Read more
Global Cord Blood Corp.: Subscriber Growth Continues With 23% EPS CAGR And 25% FCF Yield – Seeking Alpha

To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Reference ID:

Read this article:

Global Cord Blood Corp.: Subscriber Growth Continues With 23% EPS CAGR And 25% FCF Yield - Seeking Alpha

Read more
Overcoming chemotherapy resistance in leukemia with a diarrhea drug from Merck – FierceBiotech

Although acute myeloid leukemia (AML) is treatable with chemotherapy, patients often become resistant to it. Researchers at Kings College in London said theyve discovered a way to potentially reverse chemo resistance in some patients with AMLand they found it in an unlikely place.

Mercks drug Dificid, used to treat Clostridium difficile-associated diarrhea, sensitized AML to treatment with the chemotherapy drug doxorubicin and improved survival in mouse models of treatment-resistant AML, the team reported in the journal Science Translational Medicine.

The researchers focused on a subtype of AML called mixed-lineage leukemia (MLL-AML), which is known for having a high rate of recurrence after treatment. Leukemia stem cells have been blamed for the poor response to front-line chemotherapy in MLL-AML.

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.

The team started by reconstructing human AML cells from cord blood samples taken from patients with MLL-AML. They discovered that most AML stem cells originated from hematopoietic stem cells (HSCs) or common myeloid progenitors. But it was the AML cells from HSCs that were particularly resistant to chemotherapy.

RELATED: How novel combos could overcome resistance to targeted drugs in leukemia, solid tumors and more

The researchers went on to study 297 genes from the leukemia stem cells. That led them to two genes associated with doxorubicin resistance. One of those genes makes a protein called ABCC3, which is highly expressed in resistant AML, they reported.

Mercks antidiarrheal drug inhibits ABCC3, so they tried it in combination with doxorubicin against tumor samples from patients with MLL-AML. Tumors treated with the combo shrank, while solo treatment with either drug produced poor responses.

In mouse models, the combination of Dificid and doxorubicin extended survival, so much so that none of the animals died of leukemia during the study period, the researchers reported.

Several combination strategies are being examined in the treatment of chemo-resistant AML. Earlier this year, researchers from Sanford Burnham Prebys Medical Discovery Institute and the University of Glasgow, for example, published a preclinical study showing that a combination of drugs targeting the proteins MDM2 and BET eradicated AML in mouse models. And a team at Cincinnati Children's Hospital Medical Center discovered that combining mTOR inhibitors with drugs that block the genes MNK and CDK9 could counteract drug resistance in AML.

The authors of the new study from Kings College hope their findings will inspire further research into the potential of using Dificid in AML patients.

Given that the drug is already used in the clinic for diarrhea, it is possible to swiftly initiate early phase clinical trials by repurposing this drug for AML patientsin particular those poor prognostic subgroups with few treatment options, said senior author Chi Wai Eric So, a professor at Kings college, in a statement.

View original post here:

Overcoming chemotherapy resistance in leukemia with a diarrhea drug from Merck - FierceBiotech

Read more